KR102022952B1 - 백시니아 바이러스의 생산을 위한 방법 및 조성물 - Google Patents

백시니아 바이러스의 생산을 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102022952B1
KR102022952B1 KR1020147005901A KR20147005901A KR102022952B1 KR 102022952 B1 KR102022952 B1 KR 102022952B1 KR 1020147005901 A KR1020147005901 A KR 1020147005901A KR 20147005901 A KR20147005901 A KR 20147005901A KR 102022952 B1 KR102022952 B1 KR 102022952B1
Authority
KR
South Korea
Prior art keywords
vaccinia virus
cell
delete delete
virus
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147005901A
Other languages
English (en)
Korean (ko)
Other versions
KR20140058601A (ko
Inventor
데이비드 컨
존 벨
Original Assignee
신라젠(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신라젠(주) filed Critical 신라젠(주)
Publication of KR20140058601A publication Critical patent/KR20140058601A/ko
Application granted granted Critical
Publication of KR102022952B1 publication Critical patent/KR102022952B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020147005901A 2011-08-05 2012-08-03 백시니아 바이러스의 생산을 위한 방법 및 조성물 Active KR102022952B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515724P 2011-08-05 2011-08-05
US61/515,724 2011-08-05
PCT/US2012/049550 WO2013022764A1 (en) 2011-08-05 2012-08-03 Methods and compositions for production of vaccina virus

Publications (2)

Publication Number Publication Date
KR20140058601A KR20140058601A (ko) 2014-05-14
KR102022952B1 true KR102022952B1 (ko) 2019-09-20

Family

ID=46650950

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147005901A Active KR102022952B1 (ko) 2011-08-05 2012-08-03 백시니아 바이러스의 생산을 위한 방법 및 조성물

Country Status (12)

Country Link
US (3) US9719105B2 (cg-RX-API-DMAC7.html)
EP (1) EP2739293B1 (cg-RX-API-DMAC7.html)
JP (1) JP6243333B2 (cg-RX-API-DMAC7.html)
KR (1) KR102022952B1 (cg-RX-API-DMAC7.html)
CN (1) CN103732236B (cg-RX-API-DMAC7.html)
AU (1) AU2012294606B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014000787B1 (cg-RX-API-DMAC7.html)
CA (1) CA2841831C (cg-RX-API-DMAC7.html)
DK (1) DK2739293T3 (cg-RX-API-DMAC7.html)
ES (1) ES2813413T3 (cg-RX-API-DMAC7.html)
PL (1) PL2739293T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013022764A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021261892A1 (ko) * 2020-06-22 2021-12-30 코오롱생명과학 주식회사 부유세포를 이용한 백시니아 바이러스의 대량생산방법

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
AU2016313969B2 (en) 2015-06-19 2021-12-23 Sillajen, Inc. Compositions and methods for viral embolization
CN106676071B (zh) * 2015-11-06 2019-07-19 天士力创世杰(天津)生物制药有限公司 HeLa-F细胞及其用途
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CA3045228C (en) 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
CN118892540A (zh) 2017-04-21 2024-11-05 新罗杰股份有限公司 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
JP7625519B2 (ja) * 2018-11-21 2025-02-03 カリヴィル イムノセラピューティクス, インコーポレイテッド ウイルスの製造
CA3124773A1 (en) 2018-12-28 2020-07-02 Transgene M2-defective poxvirus
KR102228267B1 (ko) 2019-01-25 2021-03-17 바이로큐어 주식회사 Bhk-21 세포를 이용한 바이러스 생산방법
CN112143693B (zh) * 2019-06-28 2024-12-27 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
KR20230038496A (ko) 2020-07-13 2023-03-20 트랜스진 면역 억제의 치료
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス, インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
CN114395538A (zh) * 2022-01-19 2022-04-26 和元生物技术(上海)股份有限公司 一种促进重组病毒载体向细胞外分泌的方法
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
CN119654339A (zh) 2022-07-01 2025-03-18 特兰斯吉恩股份有限公司 包含表面活性蛋白-d和tnfsf成员的融合蛋白
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스
AU2024236322A1 (en) * 2023-03-10 2025-08-21 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
WO2008113078A1 (en) 2007-03-15 2008-09-18 Jennerex, Inc. Oncolytic vaccinia virus cancer therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
HU230198B1 (hu) * 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
WO2004014314A2 (en) 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
EP1933857A2 (en) * 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
CA2662569C (en) * 2006-08-07 2017-01-03 Japan As Represented By Director General Of National Institute Of Infectious Diseases Process for preparing live smallpox vaccine
US8003364B2 (en) * 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
WO2011017050A1 (en) 2009-07-28 2011-02-10 Corning Incorporated Synthetic microcarriers for culturing cells
KR101838472B1 (ko) * 2009-09-14 2018-03-15 신라젠(주) 종양 용해 백시니아 바이러스 병용 암 치료요법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
WO2008113078A1 (en) 2007-03-15 2008-09-18 Jennerex, Inc. Oncolytic vaccinia virus cancer therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF PROTEOME RESEARCH. 2008, vol. 7, no. 3, pages 960-968.
MOLECULAR THERAPY. 2011.07.19., vol. 19, no. 10, pages 1913-1922.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021261892A1 (ko) * 2020-06-22 2021-12-30 코오롱생명과학 주식회사 부유세포를 이용한 백시니아 바이러스의 대량생산방법

Also Published As

Publication number Publication date
AU2012294606B2 (en) 2016-10-06
US20190169578A1 (en) 2019-06-06
AU2012294606A1 (en) 2014-01-23
EP2739293A1 (en) 2014-06-11
ES2813413T3 (es) 2021-03-23
CA2841831A1 (en) 2013-02-14
JP2014521353A (ja) 2014-08-28
EP2739293B1 (en) 2020-06-10
DK2739293T3 (da) 2020-08-24
BR112014000787B1 (pt) 2021-04-13
CA2841831C (en) 2019-12-31
US9719105B2 (en) 2017-08-01
CN103732236B (zh) 2017-09-15
WO2013022764A1 (en) 2013-02-14
KR20140058601A (ko) 2014-05-14
BR112014000787A2 (pt) 2017-07-11
US20140162342A1 (en) 2014-06-12
JP6243333B2 (ja) 2017-12-06
PL2739293T3 (pl) 2020-11-16
US10767166B2 (en) 2020-09-08
CN103732236A (zh) 2014-04-16
US20170298324A1 (en) 2017-10-19
US10202581B2 (en) 2019-02-12

Similar Documents

Publication Publication Date Title
US10767166B2 (en) Methods and compositions for production of vaccina virus
RU2551982C2 (ru) Способ получения поксвирусов и композиции поксвирусов
ES2987311T3 (es) Sembrar un biorreactor de células adherentes con células no adherentes aumenta el límite de densidad de siembra y reduce el tiempo de expansión requerido
JP5945270B2 (ja) 発現産物を採取するための方法
PT1427817E (pt) Multiplicação de vírus numa cultura celular
EP3581646A1 (en) Integrated manufacturing and chromatographic system for virus production
US10851350B1 (en) Bioreactor production of virus from adherent cells
Léon et al. The EB66® cell line as a valuable cell substrate for MVA-based vaccines production
JP2015535687A (ja) 新規mvaウイルス及びその使用
Grein et al. Screening different host cell lines for the dynamic production of measles virus
CN113423825A (zh) 病毒生产方法
JP2025118611A (ja) 接着細胞からのウイルスのバイオリアクター生成
JP2022539511A (ja) ウイルスの生産方法及び採取用溶液組成物
Fernandes et al. Upstream bioprocess for adenovirus vectors
HK1194296B (en) Methods and compositions for production of vaccina virus
HK1194296A (en) Methods and compositions for production of vaccina virus
CN121006317B (zh) 一种永生化鸡胚肾上皮样细胞及其制备方法和应用
CN102827842B (zh) 靶向抑制羊痘病毒ORF095基因的序列siRNA-296
CN102851293B (zh) 靶向抑制羊痘病毒ORF095基因的序列siRNA-165
HK1180723A (en) Recombinant varicella-zoster virus
CN102796740A (zh) 靶向抑制羊痘病毒ORF095基因的序列siRNA-70
CN102417907A (zh) 靶向抑制羊痘病毒ORF095基因的siRNA序列

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20220826

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000